StatusThe thesis was presented on the 20 September, 2019 at the meeting of the Scientific Council and now it is under consideration of the National Council.
Abstract– 0.61 Mb / in romanian
3.29 Mb /
The paper is exposed on 139 page of basic text, contain introduction, 6 chapters, bibliographies (175 sources), 6 annexes, 18 tables, 11 figures. The obtained resultants was published in 18 scientific work, among that 6 articles.
Filed of study: rheumatology.
The aim of study: To asses efficiency and tolerability of biologic treatment with tocilizumab, monoteray with metotrexate and combined treatment metorexate and sulfasalazine in patient with rheumatoid arthritis (RA), and asses the impact on life quality.
Study objectives: to study efficiency and tolerability of different DMARD therapies (biological and standard) in RA, and their influences on life quality of patients. The novelty and originality: first time in Republic of Moldova was done a study for assessment (in comparison) of efficacy and tolerability of biologic treatment with anti IL6 agent (tocilizumab), with metotrexate monoterapy an combination of metotrexat and sulfasalazin in patient with rheumatoid arthritis.
Scientific problem solved in paper consist in assessment of efficacy an tolerability of biological and combined treatment in rheumatoid arthritis.
Theoretical importance of paper consisted in revealing of efficacy and tolerability of biological and combined treatment in rheumatoid arthritis.
Applied value. Is appreciated a high and stable efficacy o biologic treatment with tocilizumab in patient with rheumatoid arthritis. Was determined satisfying tolerability of tocilizumab in patient with rheumatoid arthritis, that permitted use of this therapy as “first line” therapy of rheumatoid arthritis. Use a combination of metotrexate and sulfasalizine, the same can be recommended as“first line treatment”, with a adequate monitoring of treatment. Result of the study was implemented in arthrology department on Republican Clinical Hospital “Timofei Mosneaga”, the same in course of continuing medical education of physicians in rheumatology and nephrology, Department of Internal medicine of State Medical University of Medicine and pharmacy ”Nicolae Testemiţanu”.